fashion -WSS

fashion

author：fashion 2025-08-12 06:41:59 - browse：94

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Pregnancy discrimination could be enabled by AI

explore

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

FDA approves world's first CRISPR

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Pfizer plans to depart BIO

STAT letters to the editor on burnt

hotspot

fashion

explore

Heart attack and stroke risk calculators need revising

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Moonlake's readout produced a cash windfall. Risks remain

Are infertility treatments 'essential' during the Covid

Apple is now the first public company to be valued at $3 trillion

What causes an itch? Researchers may have solved the mystery

Wildfire smoke exposes gaps in outdoor worker protections

How a Boston hospital is priming medical residents to use GPT

Affirmative action in medical school literally saved lives

Americans' trust in science, scientist continues decline: Report

explore

FDA needs staff influx to meet gene therapy needs, Marks says

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

What PEPFAR has meant on the ground in Ukraine

Stanford president’s abrupt resignation sparks debate

Congenital heart disease patients face new threat of heart failure

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

hotspot

explore

knowledge

focus